Cellares
Cellares accelerates access to cell therapies by providing manufacturing excellence through a global network of IDMO smart factories.
Classification
Profile
Funding
Funding details not yet available.
Fundraising & market
First Integrated Development and Manufacturing Organization (IDMO) using an Industry 4.0 approach to accelerate access to living cell therapies.
Biopharmaceutical and cell therapy companies requiring integrated development and mass manufacturing services for complex living drugs.
Services revenue from integrated development and manufacturing of cell therapies, likely structured through project-based or contracted manufacturing fees.
Direct B2B sales targeting biopharma leaders in the DACH region and global markets seeking advanced cell therapy manufacturing capabilities.
Strategic alliances within the biopharma ecosystem to support the integrated development and manufacturing workflow for living drugs.
High capital expenditure for integrated manufacturing technologies, R&D for Industry 4.0 processes, and specialized operational costs for living drug production.
Proprietary integrated development and manufacturing technologies, Industry 4.0 infrastructure, and specialized expertise in cell therapy production.
Developing and operating integrated technologies for cell therapy manufacturing, accelerating the production of living drugs at scale.
Partnership model focused on accelerating client timelines for life-saving therapies through integrated development and manufacturing support.
Distinct as the first IDMO; competitors are traditional CDMOs lacking the integrated development focus or the specific Industry 4.0 manufacturing approach.
Complexity and slow speed in scaling cell therapy production; lack of integrated development and manufacturing solutions for living drugs.
- Launch a “Digital Twin” pre-manufacturing service - charge a consulting fee for simulation runs; this creates an additional revenue strea
Funding validation: $257 M Series D led by BlackRock and Eclipse underscores strong investor confidence and provides runway for global expan · Regulatory endorsement: FDA Advanced Manufacturing Technology (AMT) designation confirms that the Cell Shuttle™ platform meets stringent aut · Operational proof: The operational Smart Factory in Bridgewater,
No investors recorded yet.